Gary Tunell
Neurology · Dallas, TXNPI 1528033453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,619 and has fallen 99.1% since, to $23 in 2025. That places this record below the midpoint for neurology clinicians in TX, where the typical reported total is $2,170.
Across 171 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$489
- Novartis$285
- Sanofi$196
- AbbVie$168
- Acadia Pharmaceuticals Inc$150
- UCB, Inc.$149
- plus $1K from 23 others
Across 8 payments — averaging $26,264 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$114K
- Genentech, Inc.$84K
- Avanir Pharmaceuticals, Inc.$12K
What the payments were for
- Speaking & faculty fees$1295%
- Food & beverage$2,58695%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 36 | $489 |
| Novartis | 17 | $285 |
| Sanofi | 10 | $196 |
| AbbVie(2 entities) | 13 | $168 |
| Acadia Pharmaceuticals Inc | 7 | $150 |
| UCB, Inc. | 9 | $149 |
| Acorda Therapeutics, Inc | 7 | $131 |
| Biogen | 10 | $125 |
| EMD Serono, Inc. | 13 | $122 |
| Genentech USA, Inc. | 6 | $97 |
| Amgen | 4 | $88 |
| Merz North America, Inc. | 2 | $78 |
| Greenwich Biosciences, Inc. | 5 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $65 |
| Tanabe Pharma America, Inc. | 4 | $63 |
| Grifols USA, LLC | 4 | $59 |
| MDD US Operations, LLC | 2 | $58 |
| Avanir Pharmaceuticals, Inc. | 3 | $57 |
| AstraZeneca | 3 | $51 |
| Upsher-smith Laboratories LLC | 2 | $38 |
| Promius Pharma LLC | 2 | $33 |
| Lilly USA, LLC | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Adamas Pharmaceuticals, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Pfizer | 1 | $15 |
| GE HealthCare | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $11 |
How this compares
$2,715 in reported general payments places this provider in the 50th percentile of 1,246 neurology providers in Texas.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.